Where Will Altria Be in 5 Years?

Altria’s core cigarette business is in sustained decline: volume fell from 101.4 billion cigarettes in 2020 to 68.6 billion by end-2024 with annual volume drops of 7.5% (2021), 9.7% (2022), 9.9% (2023) and 10.2% (2024), and volume down 10.6% through the first nine months of 2025. Revenue peaked at $26.2 billion in 2020 and has eased to $24.0 billion in 2024 (Q3-2025 annualized run rate ~ $24.3bn); revenue declines have been smaller than volume losses due to price increases, while buybacks have propped up EPS and the stock yields ~7.4%. If recent trends persist, the analyst projects volume could fall to ~41.5 billion and revenue to about $22.6 billion in five years, making the high yield increasingly risky for conservative income investors.

Analysis

Market structure: The pain is concentrated in legacy US combustible tobacco (MO) while alternative-nicotine makers, oral nicotine brands, and non-tobacco consumer staples (KMB/KO/PEP) stand to gain market-share and defensive flows. MO’s historical pricing power has masked steep volume elasticity; a continued ~10% annual volume decline implies mid-single-digit revenue contraction but high single-digit EPS support only if buybacks continue. Cross-asset: widening equity downside for MO should lift implied volatility, widen credit spreads on high-dividend issuers, and shift income-seeking flows from equity into IG bonds and dividend ETFs.

Risk assessment: Tail risks include an FDA menthol ban or new federal excise hikes within 12–24 months, adverse litigation or a forced write-down of non-core stakes (low-probability, high-impact). Immediate (days) risk: quarterly volume prints/management commentary; short-term (3–12 months): buyback cadence and guidance; long-term (3–5 years): structural volume shrink of 30–50% per scenario. Hidden dependencies: buybacks are masking demand erosion and may be funded by leverage; a credit-rating hit would force dividend cuts.

Trade implications: Prefer bounded bearish exposure to MO via 6–12 month put spreads to limit carry; implement a relative-value pair (short MO, long PM) to capture US-structural decline vs international/heated-tobacco optionality. Rotate 2–4% portfolio weight out of MO into high-quality dividend alternatives (KO/PEP) and healthcare defensives; use options to express conviction (buy puts or put spreads, avoid naked shorts). Entry/exit: deploy initial positions on next quarterly print if volume decline >8% y/y; trim if MO rallies >8% or if management announces credible pivot (new nicotine product roadmap or material buyout of alternatives).

Contrarian angles: The market may be overpricing permanent ruin; MO still generates >$20bn revenue and could monetize non-core stakes or pivot into oral nicotine, making select long-dated call spreads a low-cost asymmetric punt. Historical parallels (tobacco consolidation + pricing) show companies can buy time for strategic pivots, but that’s a low-odds recovery—only add convex long exposure if management commits >$2bn/yr to product diversification or M&A. Unintended consequence: aggressive buybacks increase leverage and likelihood of dividend trimming, turning the yield trap into capital loss for income buyers.

Key Decisions for Investors

• Establish a 2–3% portfolio notional bearish position on MO via a 6–12 month put spread (buy 1x ~35-delta put, sell 1x ~15-delta put) to cap premium and target >20% downside if volume declines persist; scale in on any close above 8% intraday weakness and set stop-loss to reduce to 1% notional on a sustained rally >12%.
• Initiate a relative-value pair: short MO (1.5% notional) and long PM (Philip Morris Intl, 1.5% notional) to play US combustible contraction vs international/heated-tobacco optionality; rebalance quarterly and add to the pair if MO’s quarterly cigarette volume decline exceeds 8% y/y.
• For income portfolios holding MO: reduce exposure to <=1% and redeploy proceeds (1–3% each) into KO and PEP for stable dividends and lower regulatory/legal tail risk; avoid reaching for MO’s 7% yield as a permanent income solution.
• Monitor three catalysts over the next 90 days—(a) quarterly combustible volume change (threshold: >8% y/y add to shorts), (b) management guidance on buybacks/debt (if buybacks fall >30% y/y, increase bearish exposure), and (c) any FDA/legislative signals on menthol within 6 months—if any trigger fires, increase put protection to 4–5% notional.